Onesource Specialty Pharma Limited — Investor Meet, 31-07-2026: Analysts/Institutional Investor Meet/Con. Call Updates

OneSource Specialty Pharma reported strong Q1 FY27 financial results for the quarter: Revenue reached 449 Cr (+37% YoY) and EBITDA hit 123.3 Cr (+39% YoY), driven by its Drug Device Combination (DDC) business. Semaglutide commercial launches in Canada and India were key. A second DDC cartridge line is coming online, doubling sterile production days, with another line by FY27 end. This capacity supports new customers and global market expansion. The biologics pipeline shows strong growth, with new partnerships. OneSource reiterates its FY28 outlook of $400M organic revenue and 40% EBITDA margins, confident in future growth and operational leverage.